Siemensstrasse 38 Heidelberg, BW, 69123 GermanyBIOMEX GmbH is a leading European provider of high-quality human biospecimens and comprehensive laboratory services, supporting innovation in Life Sciences and In Vitro Diagnostics (IVD). We combine a constantly expanding, clinically annotated biobank with fully customizable prospective collections and in-house analytical capabilities to deliver flexible solutions for both early-stage research and large-scale diagnostic development. Our extensive sample portfolio includes a wide variety of invasive and non-invasive human biological specimens, such as - whole blood, - plasma - cfDNA plasma - serum - bulk plasma - Peripheral mononuclear blood cells (PBMCs) - Fresh and cryopreserved Leukopaks - Cerebral Spinal Fluid (CSF) (with a large set of matched serum available in our inventory - Fresh tissue samples - Formalin-fixed, Paraffin embedded (FFPE) tissue blocks, - Tumor microarrays (TMA) , urine, feces (stool samples), and swabs. All specimens are ethically sourced under stringent governance, with both fully consented collections and dedicated IRB-approved prospective studies. Clients can define precise inclusion and exclusion criteria to target specific patient populations, disease states, or biomarker profiles, ensuring that prospective collections meet the exact needs of their research or diagnostic programs. Through our available samples at our biobank and the ability to collect samples prospectively we cover up a variety of disease specifications including oncology, neurodegenerative autoimmune, infectious, metabolic and hematologic diseases. BIOMEX maintains a constantly growing biobank of off-the-shelf samples that are directly available for immediate use. These specimens are highly characterized, analyte-verified, and rigorously quality-controlled, providing reliability and reproducibility for a broad range of research applications. We support both low-quantity samples for early-stage feasibility studies and bulk plasma for high-volume diagnostic research, assay development, and QC panel production. This flexibility allows us to serve projects ranging from exploratory research to full-scale manufacturing of diagnostic kits. Beyond specimen supply, BIOMEX operates its own in-house laboratory, enabling a range of specialized services, including assay preprocessing, immunogenicity testing, and external validation studies for proteomics and genomics. PBMCs and cellular products are HLA-characterized, and FACS-based immunophenotyping can be performed using conventional markers or custom panels, supporting detailed immune profiling, cell therapy research, and advanced immunological studies. Our laboratory capabilities streamline workflows and accelerate project timelines by allowing comprehensive sample processing, analysis, and reporting under one roof. BIOMEX also offers rapid logistics, including fresh Leukopak delivery within 24 hours in Germany most of Europe, ensuring high viability and immediate usability for time-sensitive research applications. Through this integrated approach — combining a large, ethically governed biobank, highly characterized off-the-shelf samples, customizable prospective collections, flexible supply volumes, and in-house laboratory services — BIOMEX is a trusted partner for biotechnology, pharmaceutical, and diagnostic companies. Our solutions support cell and gene therapy, immuno-oncology, biomarker discovery, translational research, drug development, and IVD assay validation, helping clients accelerate innovation while maintaining the highest standards of quality, reproducibility, and regulatory compliance.

Siemensstraße 38 Heidelberg, 69123 GermanyBIOMEX GmbH is a leading European provider of high-quality human biospecimens and comprehensive laboratory services, supporting innovation in Life Sciences and In Vitro Diagnostics (IVD). We combine a constantly expanding, clinically annotated biobank with fully customizable prospective collections and in-house analytical capabilities to deliver flexible solutions for both early-stage research and large-scale diagnostic development. Our extensive sample portfolio includes a wide variety of invasive and non-invasive human biological specimens, such as - whole blood, - plasma - cfDNA plasma - serum - bulk plasma - Peripheral mononuclear blood cells (PBMCs) - Fresh and cryopreserved Leukopaks - Cerebral Spinal Fluid (CSF) (with a large set of matched serum available in our inventory - Fresh tissue samples - Formalin-fixed, Paraffin embedded (FFPE) tissue blocks, - Tumor microarrays (TMA) , urine, feces (stool samples), and swabs. All specimens are ethically sourced under stringent governance, with both fully consented collections and dedicated IRB-approved prospective studies. Clients can define precise inclusion and exclusion criteria to target specific patient populations, disease states, or biomarker profiles, ensuring that prospective collections meet the exact needs of their research or diagnostic programs. Through our available samples at our biobank and the ability to collect samples prospectively we cover up a variety of disease specifications including oncology, neurodegenerative autoimmune, infectious, metabolic and hematologic diseases. BIOMEX maintains a constantly growing biobank of off-the-shelf samples that are directly available for immediate use. These specimens are highly characterized, analyte-verified, and rigorously quality-controlled, providing reliability and reproducibility for a broad range of research applications. We support both low-quantity samples for early-stage feasibility studies and bulk plasma for high-volume diagnostic research, assay development, and QC panel production. This flexibility allows us to serve projects ranging from exploratory research to full-scale manufacturing of diagnostic kits. Beyond specimen supply, BIOMEX operates its own in-house laboratory, enabling a range of specialized services, including assay preprocessing, immunogenicity testing, and external validation studies for proteomics and genomics. PBMCs and cellular products are HLA-characterized, and FACS-based immunophenotyping can be performed using conventional markers or custom panels, supporting detailed immune profiling, cell therapy research, and advanced immunological studies. Our laboratory capabilities streamline workflows and accelerate project timelines by allowing comprehensive sample processing, analysis, and reporting under one roof. BIOMEX also offers rapid logistics, including fresh Leukopak delivery within 24 hours in Germany most of Europe, ensuring high viability and immediate usability for time-sensitive research applications. Through this integrated approach — combining a large, ethically governed biobank, highly characterized off-the-shelf samples, customizable prospective collections, flexible supply volumes, and in-house laboratory services — BIOMEX is a trusted partner for biotechnology, pharmaceutical, and diagnostic companies. Our solutions support cell and gene therapy, immuno-oncology, biomarker discovery, translational research, drug development, and IVD assay validation, helping clients accelerate innovation while maintaining the highest standards of quality, reproducibility, and regulatory compliance.

Hans-Böckler-Straße 2a Heidelberg, 69115 GermanyBIOMEX GmbH is a leading European provider of high-quality human biospecimens and comprehensive laboratory services, supporting innovation in Life Sciences and In Vitro Diagnostics (IVD). We combine a constantly expanding, clinically annotated biobank with fully customizable prospective collections and in-house analytical capabilities to deliver flexible solutions for both early-stage research and large-scale diagnostic development. Our extensive sample portfolio includes a wide variety of invasive and non-invasive human biological specimens, such as - whole blood, - plasma - cfDNA plasma - serum - bulk plasma - Peripheral mononuclear blood cells (PBMCs) - Fresh and cryopreserved Leukopaks - Cerebral Spinal Fluid (CSF) (with a large set of matched serum available in our inventory - Fresh tissue samples - Formalin-fixed, Paraffin embedded (FFPE) tissue blocks, - Tumor microarrays (TMA) , urine, feces (stool samples), and swabs. All specimens are ethically sourced under stringent governance, with both fully consented collections and dedicated IRB-approved prospective studies. Clients can define precise inclusion and exclusion criteria to target specific patient populations, disease states, or biomarker profiles, ensuring that prospective collections meet the exact needs of their research or diagnostic programs. Through our available samples at our biobank and the ability to collect samples prospectively we cover up a variety of disease specifications including oncology, neurodegenerative autoimmune, infectious, metabolic and hematologic diseases. BIOMEX maintains a constantly growing biobank of off-the-shelf samples that are directly available for immediate use. These specimens are highly characterized, analyte-verified, and rigorously quality-controlled, providing reliability and reproducibility for a broad range of research applications. We support both low-quantity samples for early-stage feasibility studies and bulk plasma for high-volume diagnostic research, assay development, and QC panel production. This flexibility allows us to serve projects ranging from exploratory research to full-scale manufacturing of diagnostic kits. Beyond specimen supply, BIOMEX operates its own in-house laboratory, enabling a range of specialized services, including assay preprocessing, immunogenicity testing, and external validation studies for proteomics and genomics. PBMCs and cellular products are HLA-characterized, and FACS-based immunophenotyping can be performed using conventional markers or custom panels, supporting detailed immune profiling, cell therapy research, and advanced immunological studies. Our laboratory capabilities streamline workflows and accelerate project timelines by allowing comprehensive sample processing, analysis, and reporting under one roof. BIOMEX also offers rapid logistics, including fresh Leukopak delivery within 24 hours in Germany most of Europe, ensuring high viability and immediate usability for time-sensitive research applications. Through this integrated approach — combining a large, ethically governed biobank, highly characterized off-the-shelf samples, customizable prospective collections, flexible supply volumes, and in-house laboratory services — BIOMEX is a trusted partner for biotechnology, pharmaceutical, and diagnostic companies. Our solutions support cell and gene therapy, immuno-oncology, biomarker discovery, translational research, drug development, and IVD assay validation, helping clients accelerate innovation while maintaining the highest standards of quality, reproducibility, and regulatory compliance.

Hans-Bunte-Straße 6 Heidelberg, 69123 GermanyBIOMEX GmbH is a leading European provider of high-quality human biospecimens and comprehensive laboratory services, supporting innovation in Life Sciences and In Vitro Diagnostics (IVD). We combine a constantly expanding, clinically annotated biobank with fully customizable prospective collections and in-house analytical capabilities to deliver flexible solutions for both early-stage research and large-scale diagnostic development. Our extensive sample portfolio includes a wide variety of invasive and non-invasive human biological specimens, such as - whole blood, - plasma - cfDNA plasma - serum - bulk plasma - Peripheral mononuclear blood cells (PBMCs) - Fresh and cryopreserved Leukopaks - Cerebral Spinal Fluid (CSF) (with a large set of matched serum available in our inventory - Fresh tissue samples - Formalin-fixed, Paraffin embedded (FFPE) tissue blocks, - Tumor microarrays (TMA) , urine, feces (stool samples), and swabs. All specimens are ethically sourced under stringent governance, with both fully consented collections and dedicated IRB-approved prospective studies. Clients can define precise inclusion and exclusion criteria to target specific patient populations, disease states, or biomarker profiles, ensuring that prospective collections meet the exact needs of their research or diagnostic programs. Through our available samples at our biobank and the ability to collect samples prospectively we cover up a variety of disease specifications including oncology, neurodegenerative autoimmune, infectious, metabolic and hematologic diseases. BIOMEX maintains a constantly growing biobank of off-the-shelf samples that are directly available for immediate use. These specimens are highly characterized, analyte-verified, and rigorously quality-controlled, providing reliability and reproducibility for a broad range of research applications. We support both low-quantity samples for early-stage feasibility studies and bulk plasma for high-volume diagnostic research, assay development, and QC panel production. This flexibility allows us to serve projects ranging from exploratory research to full-scale manufacturing of diagnostic kits. Beyond specimen supply, BIOMEX operates its own in-house laboratory, enabling a range of specialized services, including assay preprocessing, immunogenicity testing, and external validation studies for proteomics and genomics. PBMCs and cellular products are HLA-characterized, and FACS-based immunophenotyping can be performed using conventional markers or custom panels, supporting detailed immune profiling, cell therapy research, and advanced immunological studies. Our laboratory capabilities streamline workflows and accelerate project timelines by allowing comprehensive sample processing, analysis, and reporting under one roof. BIOMEX also offers rapid logistics, including fresh Leukopak delivery within 24 hours in Germany most of Europe, ensuring high viability and immediate usability for time-sensitive research applications. Through this integrated approach — combining a large, ethically governed biobank, highly characterized off-the-shelf samples, customizable prospective collections, flexible supply volumes, and in-house laboratory services — BIOMEX is a trusted partner for biotechnology, pharmaceutical, and diagnostic companies. Our solutions support cell and gene therapy, immuno-oncology, biomarker discovery, translational research, drug development, and IVD assay validation, helping clients accelerate innovation while maintaining the highest standards of quality, reproducibility, and regulatory compliance.

Dachauerstraße 4 München, 80335 GermanyBIOMEX GmbH is a leading European provider of high-quality human biospecimens and comprehensive laboratory services, supporting innovation in Life Sciences and In Vitro Diagnostics (IVD). We combine a constantly expanding, clinically annotated biobank with fully customizable prospective collections and in-house analytical capabilities to deliver flexible solutions for both early-stage research and large-scale diagnostic development. Our extensive sample portfolio includes a wide variety of invasive and non-invasive human biological specimens, such as - whole blood, - plasma - cfDNA plasma - serum - bulk plasma - Peripheral mononuclear blood cells (PBMCs) - Fresh and cryopreserved Leukopaks - Cerebral Spinal Fluid (CSF) (with a large set of matched serum available in our inventory - Fresh tissue samples - Formalin-fixed, Paraffin embedded (FFPE) tissue blocks, - Tumor microarrays (TMA) , urine, feces (stool samples), and swabs. All specimens are ethically sourced under stringent governance, with both fully consented collections and dedicated IRB-approved prospective studies. Clients can define precise inclusion and exclusion criteria to target specific patient populations, disease states, or biomarker profiles, ensuring that prospective collections meet the exact needs of their research or diagnostic programs. Through our available samples at our biobank and the ability to collect samples prospectively we cover up a variety of disease specifications including oncology, neurodegenerative autoimmune, infectious, metabolic and hematologic diseases. BIOMEX maintains a constantly growing biobank of off-the-shelf samples that are directly available for immediate use. These specimens are highly characterized, analyte-verified, and rigorously quality-controlled, providing reliability and reproducibility for a broad range of research applications. We support both low-quantity samples for early-stage feasibility studies and bulk plasma for high-volume diagnostic research, assay development, and QC panel production. This flexibility allows us to serve projects ranging from exploratory research to full-scale manufacturing of diagnostic kits. Beyond specimen supply, BIOMEX operates its own in-house laboratory, enabling a range of specialized services, including assay preprocessing, immunogenicity testing, and external validation studies for proteomics and genomics. PBMCs and cellular products are HLA-characterized, and FACS-based immunophenotyping can be performed using conventional markers or custom panels, supporting detailed immune profiling, cell therapy research, and advanced immunological studies. Our laboratory capabilities streamline workflows and accelerate project timelines by allowing comprehensive sample processing, analysis, and reporting under one roof. BIOMEX also offers rapid logistics, including fresh Leukopak delivery within 24 hours in Germany most of Europe, ensuring high viability and immediate usability for time-sensitive research applications. Through this integrated approach — combining a large, ethically governed biobank, highly characterized off-the-shelf samples, customizable prospective collections, flexible supply volumes, and in-house laboratory services — BIOMEX is a trusted partner for biotechnology, pharmaceutical, and diagnostic companies. Our solutions support cell and gene therapy, immuno-oncology, biomarker discovery, translational research, drug development, and IVD assay validation, helping clients accelerate innovation while maintaining the highest standards of quality, reproducibility, and regulatory compliance.